Reverse Splits

[sludgehound]

ACAR R/S 1-500 open 1/27 Friday
news just now

OREM, UT -- (Marketwired) -- 01/26/17 -- ActiveCare, Inc. (OTCQB: ACAR) announced today that it will effect a 1-for-500 reverse stock split of its common stock (the "Reverse Split"). The Reverse Split was approved by the Company's stockholders. The Reverse Split will be effective and the Company's common stock will trade on a split-adjusted basis as of the opening of business on Friday, January 27, 2017 . The exercise and conversion prices of the Company's outstanding warrants and convertible notes, as well as the amount of shares issuable pursuant to the Company's equity compensation plans, will be adjusted accordingly.
Upon the effectiveness of the Reverse Split, each five hundred shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock, par value $0.00001 per share. The Company will not issue any fractional shares in connection with the Reverse Split. Fractional share interests will be rounded up. The Reverse Split will not modify the rights or preferences of the Company's common stock.
The Company's transfer agent, American Stock Transfer & Trust Company, LLC , will act as exchange agent for the Reverse Split. American Stock Transfer & Trust Company, LLC will provide stockholders of record holding certificates representing pre-split shares of the Company's common stock as of the effective date a letter of transmittal with instructions for the exchange of shares. Registered stockholders holding pre-split shares of the Company's common stock electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares via a broker or other nominee will have their positions automatically adjusted to reflect the Reverse Split, subject to brokers' particular processes, and will not be required to take any action in connection with the Reverse Split. American Stock Transfer & Trust Company, LLC can be reached at [phone] or [phone].
Additional information regarding the Reverse Split can be found in the Company's information statement filed with the U.S. Securities and Exchange Commission on September 13, 2016 , a copy of which is available at www.sec.gov.
About ActiveCare ActiveCare, Inc. focuses on providing monitoring services for individuals with diabetes. Its CareCenter is staffed around the clock by highly trained specialists offering all manner of assistance with health monitoring. Headquartered in Orem, Utah , and publicly traded on the OTC Bulletin Board under symbol ACAR, ActiveCare, Inc. is committed to providing consistent excellence in quality and safety as well as friendly care for members and caregivers alike. To learn more about ActiveCare, Inc. , visit www.activecare.com.

[Penny Gold Mine]

Pzoo 1:250

[e-ore]

ERMS - Splitting 1 for 50

http://archive.fast-edgar.com//20170126/A8ZXF22CZ222P2Z222292CZZ4E5LZ6T7G292/

[e-ore]

BETS - Splitting 1 for 100

http://archive.fast-edgar.com//20170124/AV22462CZ22RQZR2222N2ZX2TTQ77Z226292/

[e-ore]

GNBT - planning to split 1 for 1000

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11792656

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11792654

[sludgehound]

GALE R/S 1-20 on Nov. 11 down 14%

Galena Biopharma Announces 1-for-20 Reverse Stock Split: Shares Drop 14%

10:36 AM EDT, 11/01/2016 (MT Newswires) -- Galena Biopharma (GALE) shares fell 14% on Tuesday after the company announced a one-for-20 reverse stock split to take effect on Nov. 11.
The stock will begin trading on an adjusted basis on Nov. 14. As a result of the reverse stock split, the company's issued and outstanding shares of common stock will decrease to approximately 10.9 million shares, post-split
"Effecting the reverse stock split will allow us to maintain compliance with the NASDAQ Capital Market minimum bid price requirement, which we believe is in the company's best interests and the best interests of our stockholders," said CEO Mark Schwartz. "We are confident in the value of our current pipeline led by GALE-401, which is expected to initiate a pivotal, Phase 3 trial next year, and in our cancer immunotherapy assets currently in multiple clinical trials. We believe that this technical change to our capital structure puts us in a better position to advance our clinical programs and grow the company into the future."
Price: 0.20, Change: -0.03, Percent Change: -14.02
http://www.mtnewswires.com Copyright © 2016 MTNewswires. All rights reserved. MT Newswires does not provide investment advice.

[e-ore]

TMED - Splitting 1 for 150

http://archive.fast-edgar.com//20161028/AO22M22CZ22HB9Z2222G2ZXZLSACSZH28282/

[Arnold25764]

Wow that sucks

[easymoney]

Check with EPAZ think they did like 4 in the last year or year+

[flaflyersfan]

Arnold25764, it is unlimited;

KGRI did 4 in one year

GBMS did 5 in one year

FINRA is getting tougher on approving this nonsense.

Good luck.

[Arnold25764]

Anyone know how many splits a pinksheet stock can do in a year?

[Arnold25764]

$CDII 1 for 100 split the a/s,raise to 9.5 bil.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=125752656

[sludgehound]

CASC to R/S meeting Nov. 18 1-4 to 1-10

10:16 AM EDT, 10/05/2016 (MT Newswires) -- Cascadian Therapeutics (CASC) said it plans to carry out a reverse stock split to increase its share price and reduce the number of authorized and outstanding shares.
"We believe this proposed change will make our stock accessible to a wider range of institutional investors, benefiting all stockholders," Scott Myers, chief executive of the company developing breast cancer drug tucatinib, said in statement on Wednesday.
The reverse stock split ratio is proposed at no less than 1-for-4 and not greater than 1-for-10, according to the statement. Cascadian plans to hold a special shareholders' meeting on Nov. 18 to obtain approval of the reverse split, it said.
The shares fell 8.2% in early trading on Wednesday.
Price: 1.54, Change: -0.14, Percent Change: -8.18
http://www.mtnewswires.com

[e-ore]

DCLT - Splitting 1 for 30

"This Information statement is being filed with the SEC on September 16, 2016, in connection with the Joint Written Consent of the Board of Directors and the Majority Stockholders, both dated September 16, 2016, to implement a reverse stock split of the issued and outstanding shares of the Company's Common Stock on a One for Thirty (1:30) basis (the "Reverse Split")."

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11596674

[mgland]

GBSN. 1-for-80 reverse Great Basin Announces Reverse Stock Split of Common Stock
5:30 pm ET September 14, 2016 (BusinessWire) Print

Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, announced today that a 1-for-80 reverse split of its common stock will be effective at 12:01 am EDT on September 16, 2016. The Company's common stock will open for trading on the Nasdaq Capital Market on September 16, 2016 on a post-split basis. At the effective time of the reverse stock split, every 80 shares of the Company's issued and outstanding common stock, par value $0.0001, will be consolidated into one newly-issued and outstanding share of common stock, par value of $0.0001.

The reverse stock split will reduce the Company's outstanding common stock from approximately 78.4 million shares to approximately 1.0 million shares. Proportional adjustments will be made to the Company's outstanding preferred shares, stock options, warrants, and equity incentive plan. The reverse stock split will affect all holders of the Company's common stock uniformly, and will not affect any stockholder's percentage ownership interest in the Company or proportionate voting power.

Stockholders who have existing stock certificates will receive written instructions by mail from the Company's transfer agent, American Stock Transfer & Trust Company, LLC. Stockholders who hold their shares in brokerage accounts ("street name") are not required to take any action to affect the exchange of their shares. Such stockholders will be contacted by their brokers with instructions. To the extent the reverse stock split would result in a stockholder owing a fractional share, such stockholder will have the number of post-reverse split shares to which they are entitled rounded up to the next whole number of shares. No stockholders will receive cash in lieu of fractional shares.

Additional information regarding the Company's reverse stock split is available in the definitive proxy statement filed by the Company with the U.S. Securities and Exchange Commission on August 22, 2016.

About Great Basin Scientific

Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company's vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the Company's website at www.gbscience.com.

Forward-Looking Statements

[VeronicaFox]

ATYG - filed with Florida SOS for 1:5000 reverse split on 06/16/2016, but it has yet to be approved by FINRA.

[VeronicaFox]

INOH - filed with Colorado SOS for 1:1500 reverse split on 05/03/2016, but has yet to be approved by FINRA.

[e-ore]

MIHI - 1 for 10 r/s coming. Filed for it at Colorado.

"The following article is amended as set forth here:
Article Four: This Article is hereby amended to add as follows:
Each share of issued and outstanding common stock as of September 15, 2016,
is reverse split on a one for ten basis such that each old share represents
1/10 of a new share. A surrender of the old share certificate is required
to be made by each shareholder in order to receive a new certificate
reflecting the reverse split and new name except for those certificates held in "Street Name." The new split adjusted share certificates will be transmitted to the shareholders of record upon surrender of old certificates. Fractional shares will be rounded up to the nearest whole share."

[e-ore]

You're welcome. Have a good weekend

[sidedraft]

Thanks again.

[e-ore]

WCRSD "Reasons for and Potential Consequences of the Reverse Stock Split

The primary purpose for the reverse stock split is to eliminate fractional shares of our outstanding common stock and other fractions of shares that are on our books and records. Fractional shares of our common stock are outstanding due to distributions of stock made by some of our stockholders. These distributing stockholders are typically limited liability companies or partnerships that have effected distributions to their equity owners on account of those owners’ interests in those distributing stockholders. In addition, as of the date of this information statement, we have fractions of shares set forth on our books and records that resulted from a prior reverse stock split effected on June 23, 2014, which did not involve a compulsory share certificate exchange. These fractions of shares represent only the right to receive payment on account of those fractions, and as such, the Company will mail payment to these holders for his, her or its share fraction and those share fractions will be cancelled prior to effecting the reverse stock split described herein.

The Board of Directors has determined that the outstanding fractional shares and the fractions of shares remaining on our books and records are not in the best interests of the Company or its stockholders. Many if not most brokerage firms will not accept certificates representing fractional shares since those fractional shares cannot easily be sold in the public markets. As a result, our stockholders holding certificates with fractional shares are forced to bear the burden and expense of dividing their share certificate into two share certificates—one representing only whole shares and a second representing only fractional shares. This process takes significant time dealing with our transfer agent and our brokerage firm. It is not unusual for stockholders or their brokerage firm to call the Company or its legal counsel with questions about how to deal with the fractional shares, and questions posed to our legal counsel end up costing the Company legal fees. In addition, our transfer agent (like most transfer agents) charges a stockholder a fee for the exchange or replacement of share certificates.

In sum, we believe that the reverse stock split is in the best interests of our Company and our stockholders because it will:

· Make it easier and more cost effective for many of our stockholders to place their shares in brokerage;

· Make it easier and more cost effective for our stockholders to buy and sell our common stock;

· Result in the issuance of new certificates reflecting the fact that the Company recently reincorporated in the State of Delaware; and

· Result in the elimination of fractions of shares that remain on the Company’s books and records from a prior reverse stock split effected in June 2014."

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11536691

[e-ore]

Was a great thought :)

[sidedraft]

So, why even do the R/S?

[sidedraft]

Thank you very much. That blows my conspiracy theory out of the water.

[e-ore]

"If the reverse stock split is effected, then every 5,000,001 shares of our outstanding common stock will be combined into 5,000,000 shares of outstanding common stock. We will not, however, issue any fractional shares as a result of this reverse stock split. Instead, any resulting fractional shares will be rounded up to the nearest whole share of common stock. So for example, if you were a holder of 88.25 shares of common stock, then your post-split would be determined by multiplying your 88.25 shares by 5,000,000 (resulting in a product of 441,250,000), and then dividing that product by 5,000,0001 (resulting in a quotient of 88.2499824); and the resulting fractional share would be rounded up so that you would have 89 full shares after giving effect to the reverse stock split. Similarly, if you were a holder of 10,100 shares, then your post-split would be determined by multiplying your 10,100 shares by 5,000,000 (resulting in a product of 50,500,000,000), and then dividing that product by 5,000,0001 (resulting in a quotient of 10,099.998); and the resulting fractional share would be rounded up so that you would have 10,100 shares after giving effect to the reverse stock split.
The reverse stock split will affect all holders of our common stock uniformly and will not affect any stockholder’s percentage ownership interest in our Company in other than a nominal manner."

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11536691

[sidedraft]

Has anyone ever seen a R/S like this, 5,000,000:5,000,001?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=125046456

Maybe I'm right?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=125072611

[Doc Holliday]

I have never seen a RS denied. But they have to have the books half way right to get them through.

[Doc Holliday]

NSEH 1 - 1500 a month or so ago. Dropped 90% already with no volume.

[Cheesesteak_Lover]

BGNN 1-2000

[e-ore]

SIGO 1 for 1000 split coming

[Gutts2318]

tron 1-500

[sludgehound]

DRYS Agrees R/S 1-4 up pre open

DryShips Agrees 1-for-4 Reverse Stock Split: Stock Jumps More Than 3% Pre-Market

Reverse-Stock Splits Won't Help Dry-Bulk Shippers -- Market Talk

9:12 ET - It's apparently the morning that dry-bulk shippers are moving to do something about their long-depressed stock prices. Both DryShips (DRYS) and Eagle Bulk (EGLE) just announced reverse-stock splits, with EGLE's 1-for-20 move taking effect with today's trading and DRYS doing a 1-for-4 reverse split as of Aug. 15 . DRYS has been trading below $1 since mid-June, versus a prior-year level above $10 , and EGLE's split-adjusted $8.10 closing finish yesterday compares with $180 a year ago. As we've said, reverse splits often don't stop stock prices from shrinking further. With DRYS and EGLE already down 90% this year, don't expect much different with these two. ([e-mail]; @kevinkingsbury)

(END) Dow Jones Newswires
08-05-16 0912ET
Copyright (c) 2016 Dow Jones & Company, Inc.

[sludgehound]

*Comstock Resources Reports 1-for-5 Reverse Stock Split

few mins ago

[sludgehound]

DCTH Delcath Systems 1 for 16 reverse split will be effective tomorrow.
Twitter post 12mins ago

[Bazooka Shark]

LIBE 1-3500

[harr449]

Good, thanx.

[trader guy]

SEC

[harr449]

Approved by management or SEC?

[trader guy]

I've been told recently that reverse splits have become extremely hard to get approved. Anyone else have any info on this?

[sludgehound]

*Qualstar Reports 1-for-6 Reverse Stock Split em

[Arnold25764]

DIRV 1 for 35 split

[Slojab]

URHN 1:10000 Reverse.

URHN Announces New Management and Direction With LOI, Name Change and Reverse Stock Split
Newly Appointed Officers and Directors Provide Shift and New Direction for Company With Support of URHN Majority Shareholders

TROY, MI--(Marketwired - Jun 2, 2016) - Uranium Hunter Corporation ("The Company" or "URHN") (OTC PINK: URHN) announced today appointments to the Board of Directors: Li-Chung Chang as Chief Executive Officer and Director; Parashar Patel as President, Treasurer and Director, and Ting Luo as Secretary and Director.

CEO and Director Li-Chung Chang is a graduate of Taiwan Aerospace Technology College with a Major in Mechanical Engineering. Mr. Chang held the position as Sales Manager for Taiwan Real Estate and Construction Company, and was recruited in 2000 as Chief of Operations for Apollo Biotech, an organic fertilizer manufacturer in Jiang Su Province, China. Most recently, Mr. Chang was hired as Chief of Sales by Resgreen Group, a licensed direct marketing company in China.

President, Treasurer and Director Parashar Patel has been involved in the software industry for the past ten years. Employed with TR Diagnostics as an Engineering Supervisor in charge of AGC project management and AGV+AGC software development teams, Mr. Patel was also a key member of the senior technical staff and Project Manager of the Innovations Group at Android Industries and a Web Analyst to the DashboardAnywhere (DA) support team for Spherion.

Secretary and Director Ting Luo graduated from Xiang Tan University in Hunan, China with a Bachelor's Degree in Literature and was employed by Resgreen Bio Engineering Group as the Assistant to the President, responsible for daily administration, inter-department communications and public relations. In 2015, she was promoted to Executive Director of the company, in charge of strategic planning and was instrumental during the launch of internet marketing through Wechat, the largest online chatting platform in China, and for developing Sky Mall for Resgreen Group.

The Company also announced today its intent to acquire Resgreen Sky Mall Co., Ltd., an e-commerce portal and business center, internet provider and software developer with merchandise logistics and distribution through its domain: www.tc8838.com

The Company has entered into a Letter of Intent to execute a Stock Purchase Agreement on or before July 15, 2016 for the acquisition of Resgreen Sky Mall Co., Ltd, a limited liability company registered in Hunan, China. The Company further announced its proposed name change to Resgreen Group International Limited to reflect its current business and acquisition strategy.

The Board of Directors and Majority Shareholders further announced today their collective approval and plan to execute a 1 for 10000 reverse stock split of the Company's issued and outstanding common stock (rounding up any fractional numbers) effective Tuesday June 28, 2016 or soon thereafter upon approval by FINRA.

[sludgehound]

VPCO PR, vote, effective 1-20,000 today 5pm et

10:57 am ET

DANIA BEACH , Fla., June 1, 2016 /PRNewswire/ -- Vapor Corp. (OTCQB: VPCO) (the "Company"), a leading U.S.-based distributor and retailer of vaporizers, e-liquids, e-cigarettes and e-hookahs, today announced that effective at 5:00 pm, Eastern Time , on June 1, 2016 (the "Effective Time"), the Company will effect a one-for-20,000 reverse stock split of its outstanding common stock. On March 21, 2016 , the Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of incorporation to effect the reverse stock split at a ratio between 1-for-10,000 and 1-for-20,000. The Board of Directors approved the implementation of a reverse stock split and determined the appropriate reverse stock split ratio to be 1-for-20,000.
As a result of the reverse stock split, every 20,000 shares of the Company's common stock issued and outstanding as of the Effective Time will be consolidated into one issued and outstanding share, except to the extent that the reverse stock split results in any of the Company's stockholders owning a fractional share, which would be rounded up to the next highest whole share.
Quotation of the Company's common stock will continue, on a split-adjusted basis, with the opening of the markets on Thursday, June 2, 2016 , under the trading symbol "VPCOD" under the new CUSIP number 922099700. The reverse stock split reduces the number of shares of the Company's common stock outstanding from approximately five billion pre-reverse split shares to approximately 250,000 post-reverse split.
Stockholders of record who hold physical certificates should submit their old certificates to the Company's transfer agent, Equity Stock Transfer, LLC , in order to obtain new certificates. Stockholders owning shares via a broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers' particular processes, and will not be required to take any action in connection with the reverse stock split. Equity Stock Transfer, LLC can be reached at [phone].
Additional information about the reverse stock split can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 3, 2016 , a copy of which is available at www.sec.gov or at www.vapor-corp.com under the SEC Filings tab located on the Investors page.

[funnyG986]

TWDL another 1-12 RS after 1-150 back in Feb 2016 OMG

[e-ore]

CDII - Splitting 1 for 200

"This information statement is being mailed or otherwise furnished to stockholders of CD International Enterprises, Inc., a Florida corporation (formerly known as China Direct Industries, Inc.) (the "Company"), in connection with the prior receipt by the Board of Directors of approval by written consent of the holders of a majority of the Company's Common and Preferred Stock (the "Voting Capital Stock") of a proposal (the "Proposal") to approve an amendment (the "RS Amendment") to the Certificate of Incorporation to effectuate one for two hundred reverse split for the Company's common stock.

On May 12, 2016, the Company's Board of Directors has received approval by majority stockholders to approve an amendment to the Company's Certificate of Incorporation (the"RS Amendment") and the filing of said amendment with the Secretary of State of State of Florida to effectuate a Reverse Stock Split of the Company's Common Stock, $.0001 par value, by a ratio of one for two hundred with such Reverse Split to be effective about June __, 2016."

http://archive.fast-edgar.com//20160513/ADZ7522CZ22222Z222282CZZOQRMZGJH6282/

[rs99]

EZRT RS 1 for 1000 4/29/16

[sludgehound]

STEM R/S 1-12 Monday open

NEWARK, Calif. , May 06, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM),  announced today that at its annual stockholders meeting held on May 5, 2016 , the Company's stockholders voted to approve a reverse stock split of the Company's common stock at a ratio of 1-for-12. Trading of the Company's common stock on the NASDAQ Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Monday, May 9, 2016 , under the existing trading symbol "STEM" and a new CUSIP number 85857R 303.
The reverse stock split was implemented by the Company as the most appropriate way to address the Nasdaq listing requirements. In addition, the reverse split is expected to increase the available shares of common stock for future issuance enabling the Company to raise the required capital to complete our ongoing clinical efforts and over time grow our business. Finally, the higher stock price should make our shares more appealing for the financial community, including institutional investors, and the general investing public. As a result of the reverse stock split, every twelve shares of the Company's common stock issued and outstanding on the effective date will be combined into one issued and outstanding share.
The reverse stock split will reduce the number of shares of the Company’s outstanding common stock from approximately 140 million to approximately 11.6 million. Fractional shares will be rounded up to the nearest whole share and proportional adjustments will be made to the Company's outstanding stock options, warrants and equity incentive plans.
About StemCells , Inc. StemCells, Inc. is currently engaged in clinical development of its HuCNS-SC® platform technology (purified human neural stem cells) as a potential treatment for chronic spinal cord injury (SCI). The Company's Pathway Study, a Phase II proof-of-concept trial in chronic cervical SCI is actively enrolling at thirteen sites in the U.S. and Canada . Six-month interim data for the first cohort of the Pathway Study showed the first-ever clinical evidence of a treatment effect improving both upper muscle strength and motor function following cellular transplant in spinal cord injury. Top-line data from the Company's earlier Phase I/II clinical trial in chronic thoracic SCI showed measurable gains involving multiple sensory modalities and segments in seven of twelve patients enrolled in the study, including the conversion of two patients from the complete AIS-A spinal cord injury to the incomplete AIS-B spinal cord injury. The Company has also completed its Phase I/II clinical trial in geographic atrophy, the most advanced form of dry age related macular degeneration. Top-line results from this study show a positive safety profile and favorable preliminary efficacy data. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company showed preliminary evidence of progressive and durable donor-derived myelination by MRI. A Phase I study in children with Batten’s disease showed that transplantation of the cells into the brain was safe and resulted in long term survival of the cells.
Further information about StemCells, Inc. is available at http://www.stemcellsinc.com.
Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the future business operations of StemCells, Inc. (the "Company"), the prospect for continued clinical development of the Company's HuCNS-SC cells in CNS disorders, the timing of final data release in the Company’s Pathway Study in cervical spinal cord injury, and the expected use of funds raised in the Company’s completed public offering. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including risks whether the FDA or other applicable regulatory agencies, including applicable institutional review boards at one or more clinical trial sites, will permit the Company to continue clinical testing or conduct future clinical trials; uncertainties regarding the timing of patient enrollment in the Company’s Pathway Study; uncertainties regarding the Company's ability to obtain the increased capital resources needed to continue its current and planned research and development operations; uncertainty as to whether HuCNS-SC cells and any products that may be generated in the future in the Company's cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; uncertainties regarding the Company's manufacturing capabilities given its increasing preclinical and clinical commitments; uncertainties regarding the Company’s plans to increase its authorized share capital and whether the Company’s Series B warrants will become exercisable; uncertainties regarding the validity and enforceability of the Company's patents; uncertainties as to whether the Company will become profitable; and other factors that are described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2015 .


CONTACT:
Robert Haag
Managing Director
IRTH Communications
[e-mail]
1-866-976-4784

Lena Evans
Russo Partners
[phone]

Image: Primary Logo


Source: StemCells, Inc.

[waterchaser]

INOH 1:1500 (fourth RS)

http://www.sos.state.co.us/biz/ViewImage.do?fileId=20161316720&masterFileId=20071237800

[e-ore]

HNDI - Splitting 1 for 150. From today's DEF 14C

"On March 11, 2016 our Board of Directors unanimously approved the amendment to our Articles of Incorporation (the "Certificate of Amendment") to effect a reverse split on a one-new for 150-old shares basis (1:150) of our outstanding shares of common stock (the "Reverse Split") such that our outstanding shares of common stock shall decrease from 321,416,654 shares to 2,142,778 shares. Our Board of Directors has fixed the close of business on April 18, 2016 as the record date (the "Record Date") for the determination of stockholders who are entitled to receive this Information Statement. There were 321,416,654 shares of our common stock issued and outstanding on April 18, 2016.

Subsequent to our Board of Directors' approval of the amendment, on April 18, 2016, the holders of the majority of the outstanding shares of common stock of our Company as of the record date provided written consent to the Reverse Split and the filing of the Certificate of Amendment in order to give effect to the Reverse Split. We will not file the Certificate of Amendment to our Articles of Incorporation until at least 20 days after the filing and mailing of this Information Statement in definitive form. We anticipate that the definitive Information Statement will be mailed on or about May 2, 2016 to all stockholders of record as of the record date, and that the definitive Information Statement will be filed with the SEC on the same date. We anticipate that the Certificate of Amendment to our Articles of Incorporation will be filed with the Nevada Secretary of State, and the Reverse Split will become effective, on or about May 24, 2016."

[tbirdman]

CCCL 1 for 8 http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11348401&RcvdDate=4/29/2016&CoName=CHINA%20CERAMICS%20CO.%2C%20LTD&FormType=6-K&View=html